• Metabolomic Diagnostics

  Participated · Equity · Jun 2016

  Metabolomic Diagnostics’ core product, PrePsia, is a blood test taken in early pregnancy that aims to identify women at risk of developing preterm pre‑eclampsia. The company says PrePsia can enable clinicians to administer effective treatments early, potentially reducing disease incidence, improving pregnancy outcomes, and lowering treatment costs. Metabolomic received €2m in EU funding under the Horizon 2020 SME Instrument to commercialise the test. The company plans to accelerate its go-to-market strategy and market the product next year, according to CEO Charles Garvey. Enterprise Ireland is cited as a supporting organisation in the company’s development and in securing Horizon 2020 support. Metabolomic is one of only three Irish companies to receive Horizon 2020 SME Instrument funding. Metabolomic Diagnostics is a Cork, Ireland–based medical diagnostics company advancing PrePsia™, a blood screening test for pre-eclampsia in first-time pregnant mothers. The PrePsia™ test is based on metabolomic biomarker research by Prof. Louise Kenny at the INFANT Research Centre, UCC, and the programme is led by CEO Charles Garvey. The company secured an additional €1.6m in funding to finalize development of PrePsia and bring the product to market in 2017. Backers named in the funding include SOSventures, Enterprise Equity and Enterprise Ireland, alongside a number of private investors. Metabolomic Diagnostics also announced that diagnostics entrepreneur Dr. Jim Walsh has joined the board. The funds will be used primarily to complete product development and commercialization preparations for the planned 2017 launch. Metabolomic Diagnostics is a UCC spinout developing a blood test intended to predict with high accuracy which pregnant women will develop pre-eclampsia. The company aims to create a cost‑effective, reliable screening test where none currently exists. The article notes the global burden of pre-eclampsia—an estimated 70,000–80,000 maternal deaths and about 500,000 infant deaths annually—which underscores the clinical need Metabolomic targets. Management includes CEO Charles Garvey (formerly of Horizon Technology) and directors Paul Hands and Diarmuid Cahalane. The Wellcome Trust holds a small investment. Financially, the company had accumulated losses of €261,000 at end‑2013 and reported €748,000 cash on the balance sheet after its first fundraising. Leadership has reinvested alongside external backers, indicating continued investor support as it advances development.

• Swrve

  Led · Equity · May 2015

  Swrve provides a mobile engagement platform that enables marketers to deliver personalized mobile experiences and maximize engagement and monetization. The solution includes audience targeting, real-time segmentation, conversations, push notifications, in-app messaging, A/B testing, predictive models, real-time data orchestration, and rich analytics across channels. Swrve partners with brands, agencies and technology partners such as The Guardian, Condé Nast, Warner Brothers, Salesforce, Oracle and Marketo, and is installed in hundreds of apps across retail, media, travel/hospitality, entertainment, sports, games and banking. Led by CEO Christopher S. Dean, the company operates offices in San Francisco, London, Dublin and Munich. The company plans to use the new funding to expand enterprise adoption, accelerate global growth and broaden investment in its open, enterprise-grade solution. The article notes the company closed a new financing round to support those plans. Swrve provides a mobile engagement platform that lets digital marketers create targeted, real-time in-app messaging, push notifications, personalization, and audience segmentation to drive user engagement, retention, and revenue. The company says its SDK has reached one billion installs and its clients have delivered more than one billion mobile messages; the platform processes over eight billion events per day. Swrve serves major brands across verticals including financial services, media and publishing, entertainment, retail, travel/hospitality, sports, games, and banking. It recently expanded rapidly across San Francisco, New York, Dublin, London, and continental Europe and reported a period of strong growth, including 4x growth from Q3 2014. Swrve is investing in product innovation and global expansion, and has unveiled Swrve Amplify, a new omni-channel product built on its acquisition of adaptiv.io to enable real-time, cross-channel marketing campaigns. Swrve was founded by Steve Collins and Hugh Reynolds, entrepreneurs with prior exits from game middleware companies Havok and Kore. The article emphasizes that the company prioritized hiring top engineers as a core strategic focus. That hiring strategy is credited with helping Swrve secure $15m in funding. Enterprise Equity Venture Capital, represented by partner Frank Walsh, became the first investor as Swrve prepared to embark on a go-to-market journey. The piece frames the founders' track record and character as central factors in attracting investment. Swrve combines elements of an ad network, analytics solution, user engagement engine, and user acquisition tool to personalize and optimize mobile app experiences in real time. The platform offers multivariate testing, a dashboard for analysis, and real‑time personalization capabilities. Its customer base spans game makers and broader mobile‑app companies, with more than 100 firms signed on, including Activision, Warner Brothers, Beamly, Electronic Arts, and Tagged. Swrve reports more than 500 million unique device identities and processes over 3 billion events per day. The company says its customer base grew more than 300% in the past year and nongame app customers grew tenfold. It has 50 employees and plans to add another 25 employees this year to support expansion. Swrve has raised $22 million to date and is focusing on expanding sales, marketing, and engineering under new leadership. Swrve provides mobile-app analytics and engagement tools that let developers segment user bases, deliver targeted messages, offers, and discounts, and run A/B tests. The company recently added dynamic engagement scoring to its toolset to enable deeper engagement testing and to calculate the likelihood that app changes will drive revenue. Swrve surfaces charts and probability metrics that help customers evaluate variant performance and revenue impact over time. The firm charges clients between $3,000 and $15,000 per month and employs about 40 people. CEO Hugh Reynolds is quoted discussing the release and product flow. The company is based in San Francisco and Dublin.

• Converser

  Led · Seed · Apr 2013

  Converser provides an in-app communication platform via SDKs for iOS and Android that supports two-way interactions including real-time chat, marketing messages, polls, feedback, and click-to-call. It is underpinned by a self-learning CRM and a conversation engine that captures individual customer insights, enables segmentation, and supplies analytics. The company offers a free tier for a limited number of app users or basic feedback/support, and charges from $0.02¢ per monthly active user for unlimited messaging. Converser says it developed the product alongside enterprise customers and counts utility companies, banks, and insurance companies among its existing customers. The startup is opening the platform to mobile developers and has launched on the StackMob marketplace. A full suite of engagement analytics lets customers track conversation-level engagement and measure campaign ROI.

• Crescent Diagnostics

  Participated · Series A · Jul 2011

  Crescent Diagnostics Ltd develops novel tests for predicting osteoporotic fracture risk. Its core product, BQT®, is a predictive test designed to enable physicians to diagnose osteoporosis‑related fracture risk using a small nail clipping. BQT® was developed at the University of Limerick. The company plans to run additional clinical trials and use new funding to advance BQT® toward regulatory approval in the US and EU. Crescent recently raised €1.5m in a Series A to support these activities. The company is led by CEO Ernie Poku and added Enterprise Equity partner Eric Reed to its board as part of the financing.

No current team members are available.